The SUPER bullish piece in this announcement is the 7.9% EBITA run rate in Q4 which implies MAH should be running at an underlying FY24 EBITA of above $150m.
Market hasn't believed they can get to 8% yet they are now starting to deliver. Getting to an ROE of >12% becoming more likely so share price should move back towards book value in my view implying >25c or over >60% more upside from here.
IMO DYOR
- Forums
- ASX - By Stock
- MAH
- Ann: FY23 Guidance Update
Ann: FY23 Guidance Update, page-11
-
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MAH (ASX) to my watchlist
(20min delay)
|
|||||
Last
35.5¢ |
Change
-0.015(4.05%) |
Mkt cap ! $770.4M |
Open | High | Low | Value | Volume |
37.0¢ | 37.5¢ | 35.0¢ | $740.9K | 2.056M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1795 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 75151 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 52673 | 0.375 |
1 | 1906 | 0.370 |
5 | 766 | 0.365 |
2 | 14362 | 0.355 |
2 | 52404 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 1082 | 1 |
0.325 | 10434 | 1 |
0.340 | 53326 | 4 |
0.360 | 75151 | 1 |
0.365 | 1584284 | 5 |
Last trade - 16.10pm 24/09/2024 (20 minute delay) ? |
Featured News
MAH (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online